MV BioTherapeutics pipeline is based on our today's idea and goals. ApyraMed has a very large potential in several indications that can be explored at a later stage.

Pipeline • Development forecast

MV BioTherapeutics ApyraMed ApyraVax MV BioTherapeutics ApyraMed ApyraVax MV BioTherapeutics ApyraMed ApyraVax MV BioTherapeutics ApyraMed ApyraVax MV BioTherapeutics ApyraMed ApyraVax MV BioTherapeutics ApyraMed ApyraVax MV BioTherapeutics ApyraMed ApyraVax 2021 2022 2023 MV BioTherapeutics ApyraMed ApyraVax MV BioTherapeutics ApyraMed ApyraVax MV BioTherapeutics ApyraMed ApyraVax MV BioTherapeutics ApyraMed ApyraVax 2020

MV-001 • Clostridioides difficile

Clostridioides difficile infection is a world-wide serious and deadly disease

Clostridioides difficile infection (CDI) is a nosocomial, antibiotics associated infectious diarrhea characterized by a high mortality rate, in particular in people above the age of 65. Current treatments include antibiotics and fecal transplantation. Recurrence rates are 20-30% and deaths in the US over 29’000 every year. The total cost per patient is extremely high.

ApyraVax is suitable for continuous dosing, exploits the already marketed and safe Salmonella Ty21a vaccine strain (Vivotif®) and induces high-affinity secretory IgAs that ensure protection from CDI.

MV target is to complete the preclinical phase during 2021 and move into clinical Ph. I at the end of 2022.
The use of ApyraVax in Clostridioides difficile is patent pending.

MV-002 • Cancer immunotherapy

Cancer immunotherapy has therapeutic efficacy in a limited number of patients

Cancer immunotherapy with immune checkpoint inhibitors (ICIs) increases anti-tumor immunity by blocking molecules that suppress anti-tumor activity. However, only a limited fraction of patients benefits from the therapeutic response obtained with these biologic drugs. Therefore, factors that could improve the therapeutic outcome are needed. In patients responsive to the therapy with ICIs, the tumor microenvironment is replenished with fresh T cells with self-renewing capacity from sites outside the tumor. This phenomenon appears to be a key factor in explaining the clinical benefit of ICIs.

ApyraMed has shown to promote the effective generation of self-renewing anti-tumor cytotoxic T cells and synergize with ICIs in controlling tumor growth, thus resulting in superior survival in experimental models of solid tumors.

MV target is to complete the preclinical phase during 2021 and move into clinical Ph. I in 2021 and Ph. II in 2023.
The use of ApyraMed in oncology is patent pending.

MV-003 • Dysbiosis

Antibiotic-induced dysbiosis exposes the organism to various medical conditions

The intestinal mucosal surface is inhabited by a complex commensal microbiota that ensures intestinal homeostasis and organism’s physiologic functions. Antibiotic treatments can severely affect microbiota diversity and cause dysbiosis, thereby exposing the host to pathophysiological consequences, including intestinal inflammation, susceptibility to enteric infections, metabolic alterations and a number of systemic effects.

ApyraMed promotes microbiome recovery and selection of beneficial bacteria after antibiotic treatment. This results in powerful control of antibiotic-induced enteric infections and metabolic alterations. 

MV target is to complete the preclinical phase during 2021 and move into clinical Ph. I in 2023.
The use of ApyraMed in dysbiosis control is patent pending.